OneSource Specialty Pharma Management
Management criteria checks 2/4
OneSource Specialty Pharma's CEO is Neeraj Sharma, appointed in Mar 2024, has a tenure of 2.25 years. total yearly compensation is ₹6.69M, comprised of 79.2% salary and 20.8% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth ₹222.91M. The average tenure of the management team and the board of directors is 2.1 years and 1.6 years respectively.
Key information
Neeraj Sharma
Chief executive officer
₹6.7m
Total compensation
| CEO salary percentage | 79.16% |
| CEO tenure | 2.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.1yrs |
| Board average tenure | 1.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -₹738m |
| Dec 31 2025 | n/a | n/a | ₹208m |
| Sep 30 2025 | n/a | n/a | ₹406m |
| Jun 30 2025 | n/a | n/a | -₹119m |
| Mar 31 2025 | ₹7m | ₹5m | -₹173m |
| Dec 31 2024 | n/a | n/a | -₹2b |
| Jun 30 2024 | n/a | n/a | -₹3b |
| Mar 31 2024 | ₹3m | n/a | -₹4b |
Compensation vs Market: Neeraj's total compensation ($USD70.75K) is below average for companies of similar size in the Indian market ($USD496.17K).
Compensation vs Earnings: Neeraj's compensation has increased whilst the company is unprofitable.
CEO
Neeraj Sharma (54 yo)
Mr. Neeraj Sharma is Chief Executive Officer, Managing Director and Director of OneSource Specialty Pharma Limited (Formerly Stelis Biopharma Limited) since March 01, 2024 He serves as an Independent Non-E...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 2.3yrs | ₹6.69m | 0.12% ₹ 222.9m | |
| Chief Financial Officer | 1.9yrs | ₹15.78m | no data | |
| Company Secretary & Compliance officer | 3.3yrs | ₹2.75m | no data | |
| Founder & Non-Executive Director | no data | no data | 0.85% ₹ 1.6b | |
| Chief Operating Officer | 2.4yrs | no data | no data | |
| Senior Vice President of Global BD | no data | no data | no data | |
| Global Head of Injectables and Head of Corporate Strategy | no data | no data | no data | |
| Chief Quality Officer | 1.3yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data |
Experienced Management: ONESOURCE's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 2.3yrs | ₹6.69m | 0.12% ₹ 222.9m | |
| Founder & Non-Executive Director | 5.2yrs | no data | 0.85% ₹ 1.6b | |
| Independent Non-Executive Director | 1.3yrs | no data | no data | |
| Non-Executive Independent Director | 1yr | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Non-Independent Director | 1.9yrs | ₹700.00k | 0.50% ₹ 928.8m | |
| Non-Executive Independent Director | 1.3yrs | no data | no data | |
| Non-Executive Independent Director | 1.3yrs | no data | no data | |
| Non-Executive Independent Director | 2.1yrs | ₹1.00m | no data |
Experienced Board: ONESOURCE's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/15 21:31 |
| End of Day Share Price | 2026/06/15 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OneSource Specialty Pharma Limited is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nitin Agarwal | DAM Capital Advisors |
| Adhidev Chattopadhyay | ICICI Securities Ltd. |
| Abdulkader Puranwala | ICICI Securities Ltd. |